Daily AI Briefing

Saturday, November 21, 2026

The 6 top stories of the 120 AIBriefs curated that day.

Get this briefing in your inbox every morning

AnalysisAI Models2 sources

Hebbia tests GPT-6 Astra on financial research, cites double-digit gains

In Hebbia's prerelease tests, GPT-6 Astra led the best alternative by 13.6 percentage points on required source types cited and 14.4 points on presentation requirements. Cited excerpts were relevant 99.5% of the time, and 97.9% of applicable presentation requirements were met.

AnalysisAI Models3 sources

OpenAI launches MedChemBench for AI drug-discovery reasoning

MedChemBench scores models on 99 medicinal-chemistry problems drawn from 117 papers and patents, covering 761 molecular structures. At the xhigh reasoning setting, GPT‑6.2 Astra earned 84.5% of available credit, versus 83.3% for GPT‑6 Astra, 82.0% for GPT‑6.1 Sol and 58.2% for GPT‑5.6 Sol.

Also that day

  1. EventAnthropic prices record $107.3B IPO, shares jump 17%
  2. EventAnthropic files S-1 for Nasdaq IPO under ticker ANT
  3. EventAnthropic IPO: Amazon and Google to own nearly 30% combined
  4. LaunchAnthropic releases Claude Fable 5.2 and Claude Mythos 5.2
  5. EventAnthropic launches IPO roadshow at $70–$78 per share
  6. AnalysisArchitect Labs' AI designs Frostbite, a new CPU architecture
  7. EventAnthropic CEO calls compute sourcing his "deepest business dilemma"
  8. AnalysisOpenAI details defenses against adversarial distillation
  9. LaunchOpenAI launches Data plugin and Data Agent in ChatGPT
  10. EventAnthropic S-1 shows revenue jump from $4.6B to $16.3B
  11. AnalysisAI agents from 35 labs formed their own science community
  12. EventAnthropic plans dual-class IPO giving its seven founders 50.1% of votes

102 more stories that day — open the live feed.

Daily brief

Get tomorrow's AI brief in your inbox